Efficacy and Safety of Selumetinib in Pediatric Patients With Neurofibromatosis Type 1
Sign Up to like & getrecommendations! Published in 2022 at "Neurology"
DOI: 10.1212/wnl.0000000000013296
Abstract: Background and Objectives Although the recent approval of selumetinib is expected to transform the management of children with neurofibromatosis type 1 (NF1), particularly those with symptomatic and inoperable plexiform neurofibromas, no systematic review has summarized… read more here.
Keywords: efficacy safety; selumetinib; safety selumetinib; neurofibromatosis type ... See more keywords